Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji
NCT07159373Phase 3Recruiting
- Sponsor
- Medicines Development for Global Health
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of moxidectin in lymphatic filariasis (LF), scabies, strongyloidiasis, sponsored by Medicines Development for Global Health. Started Sep 2026; status: recruiting.
02
Drugs
moxidectin
03
Conditions
lymphatic filariasis (LF)scabiesstrongyloidiasis
Beyond the preview
Go deeper on NCT07159373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07159373.